United States Patent 12,589,096 (Ruxolitinib Topical) Claim Scope and US Patent Landscape
United States Patent No. 12,589,096 claims a clinical-method for treating moderate atopic dermatitis with a topical ruxolitinib formulation dosed twice daily for at least 8 weeks, using tightly defined baseline disease severity, itch response, and week-2/week-4/week-8 success thresholds. Claim scope is strongest where a product label or clinical program matches the claimed BSA (3% to 20%), itch NRS (≥4), and IGA-TS and itch reduction endpoints. The estate is likely to be actionable against generics/biosimilars are not relevant (this is a small-molecule drug) but relevant against topical ruxolitinib competitors that enter via Paragraph IV or attempt to design around by modifying dose strength, regimen frequency, endpoint definitions, baseline inclusion criteria, and salt form.
What is US Patent 12,589,096 claiming for topical ruxolitinib in atopic dermatitis?
Core claim 1 is a method-of-treatment defined by (i) product composition, (ii) dosing regimen, and (iii) patient selection and clinical response requirements.
Claim 1 essential elements (required)
-
Indication / disease state
- Treat moderate atopic dermatitis in a human patient in need thereof.
- Patient baseline:
- BSA atopic dermatitis involvement: 3% to 20%
- Baseline itch NRS: ≥4
-
Product: topical formulation
- Contains ruxolitinib or pharmaceutically acceptable salt
- Strength:
- 0.5% to 1.5% (w/w) on a free base basis
- Route: administered to the skin via a topical formulation
- Dosing frequency: two times per day
-
Treatment duration
- Continue administration for at least 8 weeks
-
Efficacy outcome requirements
- IGA treatment success (IGA-TS) at week 8:
- IGA score 0 (clear) or 1 (almost clear)
- with ≥2 grade improvement from baseline at week 8
- Itch NRS response at week 8:
- ≥4 point reduction from baseline by week 8
What the narrower claims add
- Claims 2, 3 address extension or stopping rules (12 weeks; stop after resolution post-8 weeks).
- Claims 4–5 define earlier itch response at week 2 or week 4.
- Claims 6, 9, 18, 20 fix the salt form as ruxolitinib phosphate.
- Claims 7, 16, 17 define diagnosis/study criteria using Hanifin and Rajka and disease chronicity (≥2 years).
- Claims 10–11 define earlier IGA success at week 2 or week 4.
- Claims 12–13 define itch reductions at day 1 and day 2.
- Claims 14–15 define tighter baseline severity gates:
Key practical implication
Because claim 1 and its dependents tie the method to specific baseline ranges and specific clinical endpoints at specified times, infringement depends on:
- how the accused product is used/marketed/labelled, and
- whether the claimed patient inclusion and measured outcomes are satisfied under real-world use or clinical instructions.
For product liability/labeling-centered disputes, the tight endpoint language can create room for design-around through label carve-outs (if feasible) or through clinical positioning that does not meet all claimed outcome definitions under typical use.
How broad are the composition and dosing limitations in US 12,589,096?
Strength window
- 0.5% to 1.5% (w/w) on a free base basis (claim 1)
- Dependent claims narrow to 0.5% to 1% (w/w) (claims 19–20)
This creates two practical infringement zones:
- 0.5%–1.5%: covered by claim 1
- 0.5%–1.0%: covered by claim 19 (and salt dependent claim 20)
If a competitor uses >1.5% or <0.5%, it can fall outside the claim language (subject to doctrine-of-equivalents analysis).
Salt form
- Ruxolitinib is allowed as the free base or “pharmaceutically acceptable salt” in claim 1.
- Several dependents specifically require ruxolitinib phosphate.
So the estate is not confined to phosphate only. But if a product uses another salt form (or free base), the independent claim 1 may still read on the product, while the phosphate-specific dependents would not.
Regimen
- Two times per day
- Treatment continues at least 8 weeks
- Claim 2: continue 12 weeks
- Claim 3: stop after at least 8 weeks when skin resolves dermatitis
Design-around options typically include:
- changing frequency (once daily),
- reducing typical duration below the claim minimum (less than 8 weeks),
- and/or reframing the instructions such that the method as used does not satisfy the claim’s required success definitions at week 8.
What patient selection and endpoint definitions drive infringement risk?
Baseline disease gates
- BSA 3% to 20% (claim 1)
- Narrower: BSA ≥10% (claim 14) and EASI ≥16 (claim 15)
Other gatekeeping:
- Hanifin and Rajka criteria (claims 7, 16)
- AD history ≥2 years (claims 8, 17)
These dependents matter most when a competitor targets a different population (milder BSA, lower EASI, shorter disease duration) or when clinical programs exclude those strata.
Itch endpoints
- Baseline itch: NRS ≥4 (claim 1)
- Week 8: ≥4 point reduction
- Early timepoints:
- day 1: ≥1 point reduction (claim 12)
- day 2: ≥1 point reduction (claim 13)
- week 2: ≥4 point reduction (claim 4)
- week 4: ≥4 point reduction (claim 5)
IGA endpoints
- Week 8:
- IGA score 0 or 1
- ≥2 grade improvement from baseline (claim 1)
- Early:
- Week 2: IGA 0/1 with ≥2 point improvement (claim 10)
- Week 4: IGA 0/1 with ≥2 point improvement (claim 11)
Litigation posture implication
If an accused product’s clinical trial design, endpoints, and inclusion/exclusion rules do not align with these definitions, the plaintiff’s direct infringement theory may need to lean on label or “intended use” arguments. But if clinical evidence shows these success criteria are routinely met, the claim reads more cleanly.
What do claims 2–20 imply about how the patent is meant to be used commercially?
Duration management
- Claim 1 requires ≥8 weeks
- Claim 2 adds 12-week continuation
- Claim 3 adds a stop rule tied to resolution
Commercially, this suggests the patent is aimed at a standard-of-care dosing and duration pattern typical of pivotal topical AD trials and label-derived regimens.
Early response claims
The dependency structure (day 1/day 2/week 2/week 4/week 8) indicates the applicant anticipated design-around attempts targeting only the primary 8-week endpoint. By adding multiple earlier success definitions, the patent captures scenarios where earlier response is used for marketing claims, or where intermediate trial analyses create parallel “method” theories.
Severity refinement
BSA/EASI/Hanifin-Rajka/history carve-ins imply:
- the patent holder anticipated that some competitors could attempt to treat a narrower subgroup,
- and built claim coverage across multiple severity strata.
How many independent vs dependent claims exist, and what is the claim dependency shape?
At least 1 independent claim (claim 1) with 19 dependent claims that:
- add duration (claims 2–3),
- add itch early-response thresholds (claims 4–5, 12–13),
- fix salt form as ruxolitinib phosphate (claims 6, 9, 18, 20),
- constrain diagnostic criteria and chronicity (claims 7–8, 16–17),
- add IGA early-response thresholds (claims 10–11),
- and tighten baseline severity (BSA, EASI) (claims 14–15) plus additional narrowing via claims 16–18.
This structure is typical of estates attempting to create multiple “hooks” for infringement depending on how a defendant markets and instructs use.
What patent estate surrounds US 12,589,096 for topical ruxolitinib atopic dermatitis (US scope)?
A full, accurate “surrounding estate” map requires the related application family members (continuations/divisionals), prosecution history citations, and the full list of US publication numbers. Those are not provided here, and without them the landscape cannot be completed accurately.
What can be stated from claim construction alone:
- This patent’s novelty appears tied to the specific clinical-response definitions and baseline selection for topical ruxolitinib in moderate AD.
- The estate is likely to include other claims covering:
- formulation composition ranges for topical ruxolitinib,
- methods using related timepoint endpoints,
- additional severities (e.g., EASI/BSA strata),
- and possibly specific salt forms and dosing schedules.
However, specific neighboring US patent numbers, assignees, filing dates, and expiration dates cannot be enumerated from the information provided.
When does US 12,589,096 lose exclusivity in the US?
A precise exclusivity and expiration forecast requires: filing date, priority date, PTA/adjustments, and whether the patent is tied to an FDA approval with exclusivity extensions (e.g., pediatric) or is part of a family with terminal disclaimers. Those data are not provided.
Is US 12,589,096 vulnerable to Paragraph IV challenges or generic design-around?
Paragraph IV risk is conceptually relevant, but method claims change the calculus
For a topical small molecule like ruxolitinib, generic manufacturers typically focus on:
- active ingredient (ANDA),
- formulation bioequivalence,
- and label compliance.
But because this patent is a method-of-treatment with outcome endpoints, the key legal and factual question becomes whether the accused product is used in a way that satisfies the claimed method, including:
- the patient baseline gates, and
- the success definitions at defined timepoints.
In practice, this tends to shift infringement arguments toward:
- label “intended use” and treatment algorithms,
- clinical trial data used to support label/marketing claims,
- and whether real-world dosing is consistent with the claimed regimen and response criteria.
Design-around routes visible in the claim language
A defendant can attempt to avoid read-through by changing:
- strength to outside 0.5%–1.5% (claim 1) or 0.5%–1% (claim 19),
- frequency (not “two times per day”),
- duration (typical use less than 8 weeks),
- population targeting (e.g., not moderate AD defined by BSA/itch/EASI gates),
- salt form constraints (affects dependent claims requiring phosphate),
- and possibly by avoiding clinical positioning where week-8 IGA-TS and itch NRS response targets are promised or shown.
Whether these strategies actually avoid infringement depends on claim construction, how the product is prescribed, and evidentiary support.
What is the Orange Book status of US 12,589,096?
The Orange Book listing for the specific ruxolitinib topical product and whether it cites US 12,589,096 cannot be determined from the information provided here. Without the Orange Book entry numbers and listed patents, a definitive status cannot be produced.
Which formulation and method-of-use competitors face highest read-through risk?
Highest risk is where an accused topical ruxolitinib product:
- is dosed 0.5%–1.5% free-base equivalent and BID,
- is indicated for moderate atopic dermatitis with comparable baseline stratification,
- and is supported by clinical evidence showing:
- week-8 IGA-TS (IGA 0/1 with ≥2-grade improvement),
- week-8 itch NRS reduction (≥4 points),
- with consistent baseline itch NRS ≥4 and BSA ranges overlapping 3%–20%.
Lower risk includes products:
- with non-overlapping strength outside the claim ranges,
- dosed once daily,
- or whose prescribing information or trials exclude the claimed baseline gates.
A competitor mapping requires identification of specific ruxolitinib topical products and their FDA labels and trial endpoints, which is not included here.
What manufacturing/IP barriers exist for topical ruxolitinib that could avoid or trigger infringement?
From the claim alone, manufacturing barriers that matter most are:
- ensuring the product’s free-base-equivalent strength falls within (or outside) the claim ranges,
- maintaining salt identity when phosphate-specific dependents are targeted,
- and the clinical “barrier” is how the product is used to achieve the claimed endpoint definitions.
Because this is not a composition-structure manufacturing claim, the critical barrier is how the accused method is practiced rather than a specific synthetic step.
Key Takeaways
- US 12,589,096 is a topical ruxolitinib atopic dermatitis method-of-treatment defined by dose (0.5%–1.5% w/w free base equivalent), BID regimen, duration (≥8 weeks), baseline disease metrics (BSA 3%–20%, itch NRS ≥4), and week-8 success endpoints (IGA-TS 0/1 with ≥2-grade improvement and ≥4-point itch NRS reduction).
- Dependent claims add multiple additional infringement “hooks” using earlier endpoints (day 1/day 2/week 2/week 4), tighter baseline severity (BSA ≥10%, EASI ≥16), diagnostic criteria (Hanifin-Rajka), chronicity (≥2 years), and salt form (ruxolitinib phosphate).
- The estate’s enforceability against competitors will turn on labeling, clinical evidence, and how prescribing/practice aligns with the claimed baseline gates and endpoint definitions, not only on formulation bioequivalence.
FAQs
-
Do claims requiring “IGA-TS at week 8” require those endpoints to be proven in the infringement case?
Yes, the claim language requires the method to include achieving those endpoint definitions at week 8.
-
Can a competitor avoid infringement by using ruxolitinib instead of ruxolitinib phosphate?
Claim 1 allows ruxolitinib or any pharmaceutically acceptable salt; phosphate limitations only apply to phosphate-specific dependent claims.
-
Does the patent cover only moderate atopic dermatitis patients with BSA between 3% and 20%?
Claim 1 requires that range; outside it falls outside the literal scope of claim 1.
-
Are day-1 and day-2 itch reduction limitations independently required?
They are required only for those dependent claims (12 and 13), not for claim 1.
-
Can changing the treatment duration below 8 weeks avoid claim 1?
Claim 1 requires at least 8 weeks of administration, so typical use below 8 weeks would not satisfy the claim as written.
References (APA)
- United States Patent No. 12,589,096.
